Patents by Inventor Koji Atarashi

Koji Atarashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10555978
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: February 11, 2020
    Assignee: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
  • Publication number: 20190314426
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: May 31, 2019
    Publication date: October 17, 2019
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190290753
    Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.
    Type: Application
    Filed: April 5, 2019
    Publication date: September 26, 2019
    Applicants: Riken, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190282635
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Application
    Filed: May 29, 2019
    Publication date: September 19, 2019
    Applicant: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
  • Publication number: 20190282634
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Application
    Filed: April 19, 2019
    Publication date: September 19, 2019
    Applicant: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
  • Patent number: 10342832
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: July 9, 2019
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10328108
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: June 25, 2019
    Assignee: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
  • Patent number: 10322150
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: June 18, 2019
    Assignee: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
  • Patent number: 10300137
    Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: May 28, 2019
    Assignees: RIKEN, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190134179
    Abstract: Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent.
    Type: Application
    Filed: October 15, 2018
    Publication date: May 9, 2019
    Applicants: Vedanta Biosciences, Inc., Riken
    Inventors: Kenya Honda, Bernat Olle, Koji Atarashi, Takeshi Tanoue, Hiroshi Ohno, Shinji Fukuda, Koji Hase
  • Patent number: 10238694
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: March 26, 2019
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190046591
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: October 25, 2018
    Publication date: February 14, 2019
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190046592
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Application
    Filed: October 26, 2018
    Publication date: February 14, 2019
    Applicant: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
  • Publication number: 20190030092
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: October 15, 2018
    Publication date: January 31, 2019
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190030093
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Application
    Filed: August 30, 2018
    Publication date: January 31, 2019
    Applicant: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
  • Patent number: 10183045
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: January 22, 2019
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10130695
    Abstract: Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: November 20, 2018
    Assignees: Vedanta Biosciences, Inc., RIKEN
    Inventors: Kenya Honda, Bernat Olle, Koji Atarashi, Takeshi Tanoue, Hiroshi Ohno, Shinji Fukuda, Koji Hase
  • Patent number: 10092603
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: October 9, 2018
    Assignee: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
  • Publication number: 20180243348
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10058578
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 28, 2018
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita